These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 31014225)

  • 1. CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA.
    Moreno-Mayordomo R; Ruiz M; Pascual J; Gallego de la Sacristana M; Vidriales I; Sobrado M; Cernuda-Morollon E; Gago-Veiga AB; Garcia-Azorin D; Telleria JJ; Guerrero AL
    J Headache Pain; 2019 Apr; 20(1):39. PubMed ID: 31014225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
    Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
    Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
    Diener HC; Dodick DW; Aurora SK; Turkel CC; DeGryse RE; Lipton RB; Silberstein SD; Brin MF;
    Cephalalgia; 2010 Jul; 30(7):804-14. PubMed ID: 20647171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
    J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
    Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU
    Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
    J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
    Dodick DW; Turkel CC; DeGryse RE; Diener HC; Lipton RB; Aurora SK; Nolan ME; Silberstein SD
    J Pain; 2015 Feb; 16(2):164-75. PubMed ID: 25464159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
    Negro A; Curto M; Lionetto L; Martelletti P
    J Headache Pain; 2015; 17():1. PubMed ID: 26792662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
    Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA.
    Martínez-Pías E; Guerrero ÁL; Sierra Á; Trigo J; García-Azorín D
    Toxins (Basel); 2021 Jun; 13(6):. PubMed ID: 34205832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
    Dodick DW; Silberstein SD; Lipton RB; DeGryse RE; Adams AM; Diener HC
    Cephalalgia; 2019 Jul; 39(8):945-956. PubMed ID: 31112399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
    J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A; Fontana A; Miscio AM; Zarrelli MM; Copetti M; Leone MA
    Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients.
    Eren OE; Gaul C; Peikert A; Gendolla A; Ruscheweyh R; Straube A
    Sci Rep; 2020 Jul; 10(1):11382. PubMed ID: 32647152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
    Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Makris N; Kararizou E
    J Headache Pain; 2018 Sep; 19(1):87. PubMed ID: 30225735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.